Crystals in the Substantia Nigra | ACS Chemical Neuroscience

Jun 30, 2019 - Crystals of TiO2 and CaO were detected in electron-beam exposed extracts of four substantia nigra specimens of Parkinson's disease dono...
0 downloads 0 Views 13MB Size
This is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.

Letter pubs.acs.org/chemneuro

Cite This: ACS Chem. Neurosci. XXXX, XXX, XXX−XXX

Crystals in the Substantia Nigra Adam Heller* and Sheryl S. Coffman

Downloaded via 178.159.97.78 on July 18, 2019 at 06:01:47 (UTC). See https://pubs.acs.org/sharingguidelines for options on how to legitimately share published articles.

McKetta Department of Chemical Engineering, University of Texas, Austin, Texas 78712, United States ABSTRACT: Crystals of TiO2 and CaO were detected in electron-beam exposed extracts of four substantia nigra specimens of Parkinson’s disease donors. A likely precursor of the CaO crystals is inflammatory calcium oxalate dihydrate, decomposing according to CaC2O4·2H2O → CaO + CO↑ + CO2↑ + 2H2O↑. Crystals of hydrated iron oxide, earlier reported residents of the human brain, were also found.

KEYWORDS: Parkinson’s disease, substantia nigra, crystals, calcium oxide dihydrate, titanium dioxide, iron oxide

T

he dopamine-producing substantia nigra (sn) is the locus of Parkinson’s disease (PD). As the disease progresses, an

Table 1. Detected Crystals specimen

count of crystal clusters

PD stage

year of donation

age of donor

searched squares

1 2 4 5

2016 2015 2016 2016

76 74 78 73

3 3 3 30 wt % Ti, Ca, or Fe.

Corresponding Author

*A.H. E-mail: [email protected]. Phone 1-512-471-7060. ORCID

Adam Heller: 0000-0003-0181-1246 Author Contributions

A.H. initiated the project and wrote the manuscript. S.S.C. developed the methods and performed the transmission electron microscopy. Both authors analyzed the data. Funding

A.H. thanks the Welch Foundation (Grant F-1131) for supporting this study. Notes

The authors declare no competing financial interest.

■ ■

ACKNOWLEDGMENTS The authors thank Dr. Karalee Jarvis for her expert guidance of the transmission electron microscopy. ABBREVIATIONS COD, calcium oxalate dihydrate; PD, Parkinson’s disease; TEM, transmission electron microscopy. C

DOI: 10.1021/acschemneuro.9b00318 ACS Chem. Neurosci. XXXX, XXX, XXX−XXX

Letter

ACS Chemical Neuroscience (18) Gaultier, M., Conso, F., Rudler, M., Leclerc, J. P., and Mellerio, F. (1976) [Acute ethylene glycol poisoning]. Eur. J. Toxicol Environ. Hyg 9 (6), 373−9. (19) Gambardella, R. L., and Richardson, K. E. (1977) The pathways of oxalate formation from phenylalanine, tyrosine, tryptophan and ascorbic acid in the rat. Biochim. Biophys. Acta, Gen. Subj. 499 (1), 156−68. (20) Knight, J., Madduma-Liyanage, K., Mobley, J. A., Assimos, D. G., and Holmes, R. P. (2016) Ascorbic acid intake and oxalate synthesis. Urolithiasis 44 (4), 289−297. (21) Rice, M. E. (1999) Ascorbate compartmentalization in the CNS. Neurotoxic. Res. 1 (2), 81−90. (22) May, J. M. (2012) Vitamin C transport and its role in the central nervous system. Subcell. Biochem. 56, 85−103. (23) Wong, K., Thomson, C., Bailey, R. R., McDiarmid, S., and Gardner, J. (1994) Acute oxalate nephropathy after a massive intravenous dose of vitamin C. Aust N Z. J. Med. 24 (4), 410−1. (24) Cossey, L. N., Rahim, F., and Larsen, C. P. (2013) Oxalate nephropathy and intravenous vitamin C. Am. J. Kidney Dis. 61 (6), 1032−5. (25) Mouatt-Prigent, A., Karlsson, J. O., Agid, Y., and Hirsch, E. C. (1996) Increased M-calpain expression in the mesencephalon of patients with Parkinson’s disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death? Neuroscience 73 (4), 979−87. (26) Hajieva, P., Kuhlmann, C., Luhmann, H. J., and Behl, C. (2009) Impaired calcium homeostasis in aged hippocampal neurons. Neurosci. Lett. 451, 119−123. (27) Heneka, M. T., Kummer, M. P., and Latz, E. (2014) Innate immune activation in neurodegenerative disease. Nat. Rev. Immunol 14 (7), 463−77.

D

DOI: 10.1021/acschemneuro.9b00318 ACS Chem. Neurosci. XXXX, XXX, XXX−XXX